Compare DexCom, Inc. (DXCM) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Thomson Reuters Corp — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Thomson Reuters Corp trades at $98.85 (market cap $41.16B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays a 2.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TRI | |
|---|---|---|
Market Cap | $28.06B | $41.16B |
Sector | Health | Industrials |
52-Week High | $89.53 | $211.14 |
52-Week Low | $54.84 | $76.55 |
Enterprise Value | $27.03B | $43.12B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Thomson Reuters (TRI) trades at $100.30, up 9.33% in the past 24 hours, reflecting strong momentum. The stock shows a bullish technical signal with moving averages and ADX supporting upward trends, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 19.93% net income margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR for its global print business and continued AI integration, signaling strategic growth initiatives.
The outlook for TRI is positive, driven by analyst consensus favoring a Buy rating with a $129.96 price target, implying significant upside. Key opportunities lie in AI adoption and partnership expansions, but risks include execution challenges in technology transitions and potential revenue volatility. Investors should weigh strong fundamentals against near-term overbought technicals and competitive pressures in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
